-
US envoy warns EU won't win AI race 'bringing others down'
-
Trump, Vance not 'meddling' in Hungary vote, says US envoy to EU
-
Jihadists kill 18 Nigerian troops including senior brigadier general
-
Mideast war threatens Africa's supply of humanitarian medicine
-
Seven World Cup winners start for England in Women's Six Nations opener
-
China FM vows deeper ties with North Korea on trip to Pyongyang
-
Sinner survives energy dip, end of streak to see off Machac
-
IMF expects to provide vulnerable economies hit by Iran war up to $50 bn
-
Oil prices jump back toward $100 on Mideast ceasefire doubts
-
Player tells Tiger to 'get a chauffeur'
-
Believers rejoice as Jerusalem's holy sites re-open
-
EU lawmakers want to tax Big Tech to fund budget
-
Croke Park boss eager to stage Fury-Joshua heavyweight clash in Dublin
-
Cannes Festival promises escapism in Hollywood-lite edition
-
Stabbed for saying no: Is online misogyny fueling violence in Brazil?
-
Russia's Nobel Prize-winning rights group Memorial branded 'extremist'
-
McIlroy ready for early start as 90th Masters begins
-
Fonseca eases into Monte Carlo last eight meeting with Zverev
-
Verstappen set for fresh F1 angst as engineer nears Red Bull exit - reports
-
Farhadi, Almodovar, Zvyagintsev to vie for top Cannes Festival prize
-
Ambitious Como's Champions League bid tested by Serie A leaders Inter
-
Emperor penguins listed as endangered species: IUCN
-
Six new caps for France for women's Six Nations opener
-
Calls for US-Iran truce to extend to Lebanon after Israeli strikes
-
Nepal ex-PM Oli gives defiant message after release from custody
-
Despite Middle East truce, airlines fear long-term disruptions
-
Memorial: Russia's Nobel Prize winning rights group facing 'extremism' ban
-
Artemis crew's families enthralled by messages from space
-
Champions Cup 'heartbreak' driving Toulouse revenge mission
-
Shallow Indonesian quake damages houses, injures residents
-
Nepal ex-PM Oli released from custody after 12 days: police
-
'Chills': Artemis astronauts say lunar flyby still washing over them
-
Ukraine lets firms deploy air defences against Russian attacks
-
Mountain-made: Balkan sheepdog eyes future beyond the hills
-
Escaped wolf forces school closure in South Korea
-
Three ways Orban gives himself an edge in Hungary's vote
-
Trump says US military to stay deployed near Iran until 'real agreement' reached
-
Gender-row boxer Lin targets Asian Games after bronze on comeback
-
US-Iran truce shows cracks as war flares in Lebanon
-
In Romania, many Hungarians root for Orban in vote
-
Home where young Bowie dreamt of 'fame' to open to public
-
Crude rises, stocks fall on fears over nascent Iran ceasefire
-
Waiting for DeepSeek: new model to test China's AI ambitions
-
You're being watched: Japan battles online abuse of athletes
-
US court expedites Anthropic's legal battle with Department of War
-
Badminton to trial synthetic shuttlecocks because of feather shortage
-
Firm, fast Augusta set to test golf's best in 90th Masters
-
BTS to kick off world tour after landmark Seoul comeback
-
Grand National had to change to survive, says former winning jockey
-
Maple syrup or nutella? PM Carney calls Canadian Artemis astronaut
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund ("White Lion"), centered on the retirement of approximately $2.02 million of warrant overhang.
Elimination of $2.02 Million Warrant Overhang
As part of the transaction, OSR Holdings has retired approximately $2.02 million of outstanding warrants by consolidating them into a newly issued convertible promissory note.
The Company issued a $555,555 convertible note to secure near-term liquidity to support general corporate purposes and the continued execution of strategic priorities.
In connection with the warrant retirement, the extinguished warrants were effectively incorporated into the note, bringing the total face value of the instrument to $1,055,555.
This structure enables OSR Holdings to eliminate a substantial source of potential dilution at a significant discount to the prior overhang value, representing a highly efficient balance sheet optimization.
Premium Conversion Price at $1.00 per Share
The convertible note is structured with a fixed conversion price of $1.00 per share, representing approximately a 100% premium to the Company's most recent closing price of approximately $0.49 on April 8, 2026.
The premium conversion price reflects a shared alignment with long-term shareholder value and stands in contrast to conventional discounted convertible structures.
The $1.00 level is also strategically aligned with the Company's objective of maintaining compliance with NASDAQ minimum bid requirements.
Six-Month Conversion Restriction
The note was issued as a private placement without a registration statement:
Accordingly, the note includes a six-month restriction on conversion, ensuring that no shares may be issued into the public float during this period.
This feature further supports near-term trading stability by preventing immediate dilution following the transaction.
Management Commentary
"This transaction is fundamentally about removing structural overhang and strengthening our equity story," said Peter Hwang, CEO of OSR Holdings. "By retiring over $2 million in warrant overhang into a tightly structured instrument, we are meaningfully cleaning up our cap table. Furthermore, the $1.00 conversion price and six-month restriction demonstrate a shared commitment by our investor to stabilizing our valuation as we focus on regaining NASDAQ minimum bid compliance."
The Company believes this transaction represents a meaningful step in optimizing its capital structure, removing technical barriers to equity performance, and securing near-term capital to advance its strategic priorities across its immunotherapy, degenerative disease, and medtech platforms.
Further details regarding this transaction will be included in the Company's filings with the U.S. Securities and Exchange Commission.
About White Lion GBM Innovation Fund
The White Lion GBM Innovation Fund, one of Innovate GBM's core sponsors, focuses on strategic funding opportunities in glioblastoma drug development. The Innovation Fund leverages the ecosystem curated by Innovate GBM to gain insights from the GBM community-including neuro-oncologists, scientists, and patient advocacy groups-to guide capital allocation toward the most impactful opportunities.
About OSR Holdings, Inc.
OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.
Investor Contact
OSR Holdings, Inc.
Investor Relations
[email protected]
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable U.S. securities laws, including statements regarding the Company's capital structure, liquidity, and expected benefits of the financing. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.
SOURCE: OSR Holdings, Inc.
View the original press release on ACCESS Newswire
L.Durand--AMWN